Leap therapeutics to present at the esmo 2021 virtual congress

Cambridge, mass., july 26, 2021 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the company will be presenting initial data from the distinguish study, a phase 2a clinical trial evaluating leap's anti-dickkopf-1 (dkk1) antibody, dkn-01, in combination with tislelizumab, beigene's ltd.
LPTX Ratings Summary
LPTX Quant Ranking